4de Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retina Eye Res, 2011,30:452-470.
5RosenzweiS HL, Planck SR, Rosenbaum JT. NLRs in the immune privileged sites. Curr Opin Pharmaco1,2011,11:423 -428.
6Du L,Kijlstra A, Yang P. Immune response genes in uveitis. Ocul Immunol Inflamm ,2009,17:249-256.
7Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behqet patients with active uveitis. Invest Ophthalmol Vis Sci, 2008,49:3058-3064.
8Wang C, Tian Y, Lei B, et al. Decreased 1L-27 expression in association with an increased Thl7 response in Vogt-Koyanagi- Harada disease. Invest Ophthalmol Vis Sci ,2012,53:4668-4675.
9Sun M,Yang P, Du L, et al. Contribution of CIM + CD25 +T cells to the regression phase of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci,2010,51:383-389.
10Ruggieri S, Frassanito MA, Dammacco R, et al. Treg lymphocytes in autoimmune uveitis. Ocul Immunol Inflamm,2012,20:255-261.
